Hepatic cavernous hemangioma is the most common benign tumor of liver, its prevalence is 7.3%, accounting for 84% of the benign tumors of the liver, predominantly in females, and we usually refer to those with a diameter larger than 5cm as giant cavernous hemangioma. Patients are asymptomatic in the early stage, often found during physical examination. For those with huge tumors, there may be epigastric mass, abdominal pain, abdominal distension, gastrointestinal or diaphragmatic compression symptoms. Hepatic cavernous hemangioma is rarely malignant, less than 5cm, slow-growing, generally do not need special treatment. However, fast-growing and huge hepatic hemangioma not only affects the normal life of patients, but also has the risk of spontaneous or traumatic rupture and bleeding, and once bleeding, the mortality rate is high. Traditional treatment is mainly based on surgery, with the development of interventional therapy, interventional therapy has become one of the safest and most effective methods to treat hepatic cavernous hemangioma, so that patients can completely avoid traumatic surgery. Interventional therapy for hepatic cavernous hemangioma is mainly through the vascular route, i.e., through the femoral artery puncture access, the catheter that has been about 1.5mm is selected into the hepatic artery, and after clarifying the blood supply artery of the hepatic hemangioma, the blood vessel of the tumor is embolized, so that the tumor lacks of blood supply, the abnormal blood vessel network is occluded, and it gradually atrophies. This treatment method has precise efficacy, patients have little pain and quick recovery, they can walk on the ground in 10 hours after the operation, and most of the patients can be discharged from the hospital after 3-5 days of observation.